Welcome to our dedicated page for Utime SEC filings (Ticker: WTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The UTime Limited (Nasdaq: WTO) SEC filings page collects the company’s regulatory disclosures, primarily furnished on Form 6-K as a foreign private issuer. These documents explain how UTime describes its business as a consumer electronics and mobile communications company focused on the design, development, manufacture, production, sales and brand operation of mobile devices and smart wearable devices, along with OEM/ODM and Electronics Manufacturing Services for other brands. Through these filings, investors can review official information on product launches, capital raising, governance changes and listing compliance.
UTime’s recent Form 6-K reports include press releases about the launch of a smartwatch with integrated blood pressure monitoring, the release of a smart ring for sleep and continuous health monitoring, and the promotion of smart wearable devices to more international markets. Other 6-Ks cover a Memorandum of Understanding with Hainan Fuxinyi Investment Co., Ltd. to co-develop a digital eldercare services platform, and a procurement agreement for smart health devices through its Hong Kong subsidiary with Tumu Vertex LLC. Filings also describe UTime’s exploration of AI-based health data analysis models using continuous physiological data from its wearables.
From a capital markets perspective, UTime has filed 6-Ks detailing a $25 million best-efforts public offering of units consisting of Class A ordinary shares and warrants, as well as a registered direct offering under a shelf registration statement on Form F-3. Additional filings discuss a private placement used to address Nasdaq’s stockholders’ equity requirement and the company’s plan for a 1-for-100 reverse stock split to support compliance with Nasdaq’s minimum bid price rule.
Corporate governance and structural changes are also documented in these filings, including board resignations and new director appointments, the resignation of the Chief Operating Officer, and the discontinuation and divestiture of certain subsidiaries. By reviewing UTime’s SEC filings alongside AI-powered summaries, readers can quickly identify key topics such as financing terms, listing status, business focus in mobile devices and health wearables, and the company’s approach to eldercare and health data initiatives.
UTime Limited reported the results of its extraordinary general meeting, where shareholders approved several major corporate actions aimed at adjusting the company’s capital structure and maintaining its Nasdaq listing.
Shareholders representing 5,311,000 Class A ordinary shares, or about 62.76% of the 8,462,243 Class A ordinary shares entitled to vote, formed a quorum. All four proposals passed unanimously. Investors approved a "Current Share Consolidation" and a large share capital increase that creates up to 900,000,000 Class A ordinary shares with updated par values, alongside 100,000,000 Class B ordinary shares.
They also approved replacing the Second Amended and Restated Memorandum and Articles of Association with a Third Amended and Restated version, reflecting the new structure. In addition, shareholders authorized a potential future consolidation of Class A ordinary shares at a ratio between 10:1 and 200:1 within the next twelve months, to help regain and maintain compliance with Nasdaq listing rules. Following the meeting, the board set the Current Share Consolidation ratio at 5:1, which will take effect once Nasdaq notification requirements are satisfied.
UTime Limited has called an extraordinary general meeting on January 26, 2026 to seek shareholder approval for several major share structure changes aimed at maintaining its Nasdaq listing. The Board is asking investors to approve a current reverse share consolidation of the Class A ordinary shares at either a five‑for‑one or six‑for‑one ratio, which is intended to lift the per‑share trading price above the $1.00 Nasdaq minimum.
If that consolidation is approved, UTime also proposes a large increase in authorized share capital, expanding Class A capacity up to 900,000,000 shares (with unchanged 100,000,000 Class B shares), and adopting a new set of Third Amended and Restated Memorandum and Articles of Association reflecting these changes. A further proposal would authorize the Board, for the next 12 months, to implement one or more additional future consolidations of Class A shares at ratios between 10:1 and 200:1, if needed to regain or maintain Nasdaq compliance. The company highlights risks that any consolidation may not sustain a higher price and could reduce liquidity, but states it does not view these actions as a step toward going private.
UTime Limited completed a private share sale to raise new funding. The company entered a share purchase agreement with certain investors to issue 4,550,000 Class A ordinary shares at $0.20 per share, for a total purchase price of $910,000, payable in USD or USDT equivalent. The transaction closed on January 20, 2026.
The company plans to use the net proceeds from this financing for working capital and general corporate purposes, helping fund its day-to-day operations and broader business needs. The shares were issued under Regulation S of the U.S. Securities Act, meaning they were sold in an offshore transaction to non-U.S. persons subject to transfer restrictions and a distribution compliance period.
UTime Limited reported that its Chief Operating Officer, Yihuang Chen, resigned effective immediately on December 12, 2025. The company stated that Mr. Chen’s resignation was not due to any disagreement regarding its operations, policies, or practices, suggesting the departure is not tied to a disclosed internal dispute.
The company also indicated that it has not yet decided whether to hire a replacement Chief Operating Officer, leaving its future leadership structure for this role undecided. The report was signed by Chief Executive Officer Hengcong Qiu, emphasizing that the change is an official, board-level leadership transition.
UTime Limited reported that shareholders approved a Share Consolidation at an extraordinary general meeting on November 10, 2025. Voting results were 81,671,284 for, 1,994,216 against, and 25,928 abstentions. Holders of 83,691,428 Class A ordinary shares voted out of 194,410,153 issued and outstanding entitled to vote.
No fractional shares will be issued; any fractional entitlement will receive one full post‑consolidation share. The company anticipates its Class A ordinary shares will begin trading on a Share Consolidation basis on November 21, 2025. An amendment to the memorandum and articles will be filed with the Cayman Islands General Registry on or about November 11, 2025, and a related press release is provided as an exhibit.
UTime Limited filed a Form 6-K noting it issued a press release on November 5, 2025. The company said it is actively promoting its smart wearable devices to more international markets through its existing global distribution channels and partner network.
The filing includes the press release as Exhibit 99.1 and reflects a focus on expanding the reach of UTime’s wearables by leveraging current partners rather than new distribution structures.
UTime Limited (WTO) furnished a Form 6-K noting it issued a press release on its ongoing exploration in health data analysis, particularly the potential application of artificial intelligence technologies. The filing identifies the press release as Exhibit 99.1. This is an informational update about the company’s R&D focus area and does not describe a transaction or financing. The report is signed by Chief Executive Officer Hengcong Qiu.
UTime Limited furnished a Form 6‑K noting it issued a press release announcing the release of its smart ring product. The company states the press release is attached as Exhibit 99.1.
The announcement is dated October 30, 2025. This filing serves to formally report the product release to U.S. markets and provide the associated press release for reference.
UTime Limited reported the launch of a smartwatch with integrated blood pressure monitoring, expanding its product portfolio in the health technology sector. The update was disclosed via a Form 6-K and accompanied by a press release dated October 28, 2025.
This addition signals a push into health-focused wearables, aligning the company with growing demand for biometric tracking devices. The filing did not include financial details or performance metrics for the new product.
UTime Limited filed an amended Form 6-K to correct the record date tied to its upcoming Extraordinary General Meeting of Shareholders. The amendment updates Exhibit 99.1.
The Extraordinary General Meeting for holders of the Company’s Class A and Class B ordinary shares is planned for November 10, 2025 at 10:00 AM EST. UTime also furnished the meeting Notice and a Form of Proxy Card as Exhibits 99.1 and 99.2.